Education

M.D., 05/2017 - Medicine, The Johns Hopkins School of Medicine
M.P.H., 05/2016 - Epidemiology & Biostatistics, The Johns Hopkins School of Public Health
Sc.B, 05/2012 - Neuroscience, Economics, Brown University

Honors & Awards

  • 2024
    Women in Urologic Oncology Best Abstract Award, Society of Urologic Oncology Meeting
  • 2024
    Reviewer of the Month, The Journal of Urology 
  • 2024
    1st Place Overall Poster at Western Section AUA Meeting
  • 2024-2025
    ASCO Young Investigator Award 
  • 2023-2024
    Urology Care Foundation Research Scholar Award 
  • 2022
    1st Place NorCal Resident Research Contest (Basic Science category)
  • 2021-2022
    Urology Care Foundation Resident Research Award  
  • 2020
    Women in Urologic Oncology Best Abstract Award, Society of Urologic Oncology Meeting
  • 2019
    Coffey-Krane Award from BJUI – Best Paper by a Trainee 
  • 2019
    Western Section AUA Resident Scholarship Award
  • 2018
    Julius R. Krevans Award for Clinical Excellence
  • 2016
    Urologic Oncology Symposium Travel Award
  • 2016-2017
    Sexual Medicine Society of North America Scholar Grant
  • 2015-2016
    NIH TL1 Predoctoral Clinical Research Program Trainee

Selected Publications

  1. Shee K, Song JJ, Cowan JE, Wang L, Nie J, Chappidi M, Washington SL, Nguyen HG, Cooperberg MR, Shinohara K, Carroll PR The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era.  View on PubMed
  2. Chappidi MR, Newcomb LF, Zheng Y, Liu M, Schenk JM, Zhu K, de la Calle CM, Brooks JD, Carroll PR, Dash A, Filson CP, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Wagner AA, Nelson PS, Lin DW Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study.  View on PubMed
  3. Chappidi MR, Lin DW, Westphalen AC Role of MRI in Active Surveillance of Prostate Cancer.  View on PubMed
  4. Chappidi MR, Lin DW, de la Calle CM Editorial Comment.  View on PubMed
  5. Chappidi MR, de la Calle CM Editorial Commentary.  View on PubMed
  6. Chappidi MR, Iravani A, Stambler N, Baskaran S, DiPippo VA, Denes BS, Lin DW Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.  View on PubMed
  7. Chappidi MR, Gore JL Editorial Commentary.  View on PubMed
  8. Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Eur Urol Oncol. 2024 Apr; 7(2):222-230.  View on PubMed
  9. Chappidi MR, Escobar D, Meng MV, Washington SL, Porten SP. Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols. Urol Oncol. 2023 08; 41(8):355.e19-355.e28.  View on PubMed
  10. Shee K, Washington SL, Cowan JE, de la Calle CM, Baskin AS, Chappidi MR, Escobar D, Nguyen HG, Cooperberg MR, Carroll PR. Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. J Urol. 2023 01; 209(1):198-207.  View on PubMed
  11. Chappidi MR, Bell A, Cowan JE, Greenberg SA, Lonergan PE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2022 05; 207(5):1001-1009.  View on PubMed
  12. Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, Kaimakliotis HZ, Konety B, Liao JC, Pohar K, Steinberg GD, Taylor JM, Tyson MD, Willard B, Lotan Y, Porten SP, Kates M. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. J Urol. 2022 Mar; 207(3):534-540.  View on PubMed
  13. Marrone MT, Mondul AM, Prizment AE, Couper D, Barber JR, Chappidi MR, Joshu CE, Platz EA Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study.  View on PubMed
  14. Yang H, Lee HH, Martin-Tuite P, Chappidi M, Bowman M, Hamouche F, Ahn J, Stoller M, Braehler M, Chi T The erector spinae plane block can facilitate outpatient stone surgery by reducing breakthrough pain.  View on PubMed
  15. Chappidi MR, Welty C, Choi W, Meng MV, Porten SP. Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort. Urology. 2021 10; 156:104-109.  View on PubMed
  16. Yang H, Chappidi M, Overland M, Ahn J, Bayne D, Chi T Live Renal Ultrasonography Facilitates Double-J Ureteral Stent Insertion at the Bedside: A Pilot Study for the COVID-19 Era.  View on PubMed
  17. Moran D, Wu AW, Connors C, Chappidi MR, Sreedhara SK, Selter JH, Padula WV Cost-Benefit Analysis of a Support Program for Nursing Staff.  View on PubMed
  18. Simms A, Chappidi M, Yang H, Hampson L, Breyer B, Cohen AJ Urethral Defect in Setting of Recurrent Urethral Foreign Body Insertion.  View on PubMed
  19. Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ Reply by Authors.  View on PubMed
  20. Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models.  View on PubMed

Go to UCSF Profiles, powered by CTSI